SEQUENT WEEKLY long after breakout
View is mine money is yours DYOR before investing or trading
expecting a bullish view in SEQUENT
About
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Market Cap ₹ 3,533 Cr.
Current Price ₹ 142
High / Low ₹ 156 / 86.0
Stock P/E
Book Value ₹ 26.3
Dividend Yield 0.00 %
ROCE 0.90 %
ROE -2.46 %
Face Value ₹ 2.00
Promoter holding 52.8 %
Change in Prom Hold -0.01 %
Sales growth -3.60 %
Profit growth 73.3 %
Dividend yield 0.00 %
Current ratio 1.31
Profit after tax ₹ -16.7 Cr.
Price to book value 5.38
Sales ₹ 1,370 Cr.
Sales Qtr ₹ 361 Cr.
Qtr Sales Var -1.49 %
Qtr Profit Var 107 %
EVEBITDA 54.6
Return over 3months 13.3 %
Price to Earning
ROCE 0.90 %
Debt ₹ 488 Cr.
Return on equity -2.46 %
Cons
- Stock is trading at 5.38 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.68% over past five years.
- Company has a low return on equity of -1.84% over last 3 years.
- Can long after breakout expecting a quick move to 1st target
- cup and handle pattern
- DIIs increased their holding stake
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 5%
5 Years: %
3 Years: %
TTM: 73%
Stock Price CAGR
10 Years: 7%
5 Years: 15%
3 Years: -22%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 4%
3 Years: -2%
Last Year: -2%
expecting a bullish view in SEQUENT
About
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Market Cap ₹ 3,533 Cr.
Current Price ₹ 142
High / Low ₹ 156 / 86.0
Stock P/E
Book Value ₹ 26.3
Dividend Yield 0.00 %
ROCE 0.90 %
ROE -2.46 %
Face Value ₹ 2.00
Promoter holding 52.8 %
Change in Prom Hold -0.01 %
Sales growth -3.60 %
Profit growth 73.3 %
Dividend yield 0.00 %
Current ratio 1.31
Profit after tax ₹ -16.7 Cr.
Price to book value 5.38
Sales ₹ 1,370 Cr.
Sales Qtr ₹ 361 Cr.
Qtr Sales Var -1.49 %
Qtr Profit Var 107 %
EVEBITDA 54.6
Return over 3months 13.3 %
Price to Earning
ROCE 0.90 %
Debt ₹ 488 Cr.
Return on equity -2.46 %
Cons
- Stock is trading at 5.38 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.68% over past five years.
- Company has a low return on equity of -1.84% over last 3 years.
- Can long after breakout expecting a quick move to 1st target
- cup and handle pattern
- DIIs increased their holding stake
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 5%
5 Years: %
3 Years: %
TTM: 73%
Stock Price CAGR
10 Years: 7%
5 Years: 15%
3 Years: -22%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 4%
3 Years: -2%
Last Year: -2%
Trade active
bought @140Trade active
BREKOUT, Good volume and momentum still a buy zone
upper circuit move possible in next week
Trade closed: target reached
3rd target hit 25% from my buy zone
still holding the trade full quantity
Note
next target : 202 ,225 ,240Note
TSL to 140Note
short term target hit all 3Trade closed: target reached
50% move from my entry exited half quantity holding other half with a tailed stoploss
Trade active
16% move today as i said Trade closed: target reached
almost 70% from my entry , within 2 month
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.